Bridging a patient with acute liver failure to liver transplantation by the AMC-bioartificial liver

61Citations
Citations of this article
26Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Recently a phase I clinical trial has been started in Italy to bridge patients with acute liver failure (ALF) to orthotopic liver transplantation (OLT) by the AMC-bioartificial liver (AMC-BAL). The AMC-BAL is charged with 10 × 109 viable primary porcine hepatocytes isolated from a specified pathogen-free (SPF) pig. Here we report a patient with ALF due to acute HBV infection. This patient was treated for 35 h by two AMC-BAL treatments and was bridged to OLT. There was improvement of biochemical and clinical parameters during the treatment. No severe adverse events were observed during treatment and follow-up of 15 months after hospital discharge. Possible porcine endogenous retrovirus (PERV) activity could not be detected in the patient's blood or blood cells up to 12 months after treatment.

Cite

CITATION STYLE

APA

Van de Kerkhove, M. P., Di Florio, E., Scuderi, V., Mancini, A., Belli, A., Bracco, A., … Chamuleau, R. A. F. M. (2003). Bridging a patient with acute liver failure to liver transplantation by the AMC-bioartificial liver. Cell Transplantation, 12(6), 563–568. https://doi.org/10.3727/000000003108747163

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free